Tags

Type your tag names separated by a space and hit enter

Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
J Alzheimers Dis. 2018; 62(1):399-408.JA

Abstract

Joint analysis of amyloid and metabolic PET patterns across healthy, mild cognitive impairment (MCI), and Alzheimer's disease (AD) subjects was performed using baseline 18F-florbetapir and 18F-FDG PET of 684 subjects from the ADNI (251 normal, 204 stable MCI, 85 AD converters, and 144 AD). Correlation between regional amyloid and metabolic uptake was measured and predictive value of PET profile regarding AD conversion in cognitively impaired subjects was assessed using survival analysis and support vector machine classification (SVM). The highest correlations were found in the temporal cortex, precuneus, and posterior cingulum. With respect to normal controls, amyloid load increase was diffuse and early in MCI subjects, whereas metabolism decrease occurred later and predominated in temporo-parietal, precuneus, and cingulate cortices. Five-year AD conversion rates in cognitively impaired subjects were 5%, 22%, 42%, and 78% in amyloid-/FDG-, amyloid-/FDG+, amyloid+/FDG-, and amyloid+/FDG+ subjects respectively (mean follow-up 37±14 months). Using SVM, the combination of ADAS-cog score, amyloid PET, and FDG PET yielded better performance in predicting AD conversion (77% accuracy; 58% positive predictive value; 88% negative predictive value) than ADAS-cog (72%; 52%; 86%), amyloid PET (72%; 52%; 87%), and FDG PET (67%; 47%; 84%). This study attests the complementary value of amyloid and FDG PET in MCI assessment and the efficiency of combined cognitive, amyloid, and metabolic scores to predict AD conversion.

Authors+Show Affiliations

Department of Nuclear Medicine, Montpellier University Hospital, Montpellier, France. Department of Nuclear Medicine, Purpan University Hospital, Toulouse, France. PhyMedExp, INSERM, CNRS, Montpellier University, Montpellier Cedex, France.Department of Nuclear Medicine, Montpellier University Hospital, Montpellier, France. PhyMedExp, INSERM, CNRS, Montpellier University, Montpellier Cedex, France.Department of Nuclear Medicine, Purpan University Hospital, Toulouse, France. ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

29439345

Citation

Ben Bouallègue, Fayçal, et al. "Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data From the ADNI." Journal of Alzheimer's Disease : JAD, vol. 62, no. 1, 2018, pp. 399-408.
Ben Bouallègue F, Mariano-Goulart D, Payoux P, et al. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI. J Alzheimers Dis. 2018;62(1):399-408.
Ben Bouallègue, F., Mariano-Goulart, D., & Payoux, P. (2018). Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI. Journal of Alzheimer's Disease : JAD, 62(1), 399-408. https://doi.org/10.3233/JAD-170833
Ben Bouallègue F, et al. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data From the ADNI. J Alzheimers Dis. 2018;62(1):399-408. PubMed PMID: 29439345.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI. AU - Ben Bouallègue,Fayçal, AU - Mariano-Goulart,Denis, AU - Payoux,Pierre, AU - ,, PY - 2018/2/15/entrez PY - 2018/2/15/pubmed PY - 2019/3/26/medline KW - Alzheimer’s Disease Neuroimaging Initiative KW - Alzheimer’s disease KW - FDG PET KW - amyloid PET KW - mild cognitive impairment SP - 399 EP - 408 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 62 IS - 1 N2 - Joint analysis of amyloid and metabolic PET patterns across healthy, mild cognitive impairment (MCI), and Alzheimer's disease (AD) subjects was performed using baseline 18F-florbetapir and 18F-FDG PET of 684 subjects from the ADNI (251 normal, 204 stable MCI, 85 AD converters, and 144 AD). Correlation between regional amyloid and metabolic uptake was measured and predictive value of PET profile regarding AD conversion in cognitively impaired subjects was assessed using survival analysis and support vector machine classification (SVM). The highest correlations were found in the temporal cortex, precuneus, and posterior cingulum. With respect to normal controls, amyloid load increase was diffuse and early in MCI subjects, whereas metabolism decrease occurred later and predominated in temporo-parietal, precuneus, and cingulate cortices. Five-year AD conversion rates in cognitively impaired subjects were 5%, 22%, 42%, and 78% in amyloid-/FDG-, amyloid-/FDG+, amyloid+/FDG-, and amyloid+/FDG+ subjects respectively (mean follow-up 37±14 months). Using SVM, the combination of ADAS-cog score, amyloid PET, and FDG PET yielded better performance in predicting AD conversion (77% accuracy; 58% positive predictive value; 88% negative predictive value) than ADAS-cog (72%; 52%; 86%), amyloid PET (72%; 52%; 87%), and FDG PET (67%; 47%; 84%). This study attests the complementary value of amyloid and FDG PET in MCI assessment and the efficiency of combined cognitive, amyloid, and metabolic scores to predict AD conversion. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/29439345/Joint_Assessment_of_Quantitative_18F_Florbetapir_and_18F_FDG_Regional_Uptake_Using_Baseline_Data_from_the_ADNI_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-170833 DB - PRIME DP - Unbound Medicine ER -